EPA0041 Effect on time of SIVmac251 acquisition by passive administration of monoclonal antibodies recognizing SIV V2 in either the CH59-like coil/helical or the b-sheet conformationsE-posterHost immune responses, vaccines and immunotherapies
EPA0042 Identification and characterization of HIV-1-specific CD8+ T cells in highly HIV-1 exposed but uninfected MsM in VietnamE-posterHost immune responses, vaccines and immunotherapies
EPA0043 Favourable transcriptomic signature of HIV-specific CD8 T cells in response to single anti-PD1 dose in people with HIV on ART and cancerE-posterHost immune responses, vaccines and immunotherapies
EPA0044 CX3CR1+ macrophages as guardians of the intestinal barrier: lessons learnt from non-human primates exposed to SIV or SARS CoV-2E-posterHost immune responses, vaccines and immunotherapies
EPA0045 Longitudinal humoral and celular immune responses to mRNA SARS-CoV-2 vaccination in adolescents living with HIVE-posterHost immune responses, vaccines and immunotherapies
EPA0046 Immunogenicity of conjugate meningococcal ACWY-TT vaccine in adolescents living with HIVE-posterHost immune responses, vaccines and immunotherapies
EPA0047 Cryo-EM analysis provide structural insights for broad HIV-1 neutralization by a heavy chain matured antibody from an Indian pediatric elite-neutralizer ​E-posterHost immune responses, vaccines and immunotherapies
EPA0048 Feasibility of iNKT cells as an immunotherapeutic HIV cure interventionE-posterHost immune responses, vaccines and immunotherapies
EPA0049 HIV vaccine candidate efficacy mediated by epigenetic changes in CD14+ cells and cAMP-dependent efferocytosisE-posterHost immune responses, vaccines and immunotherapies
EPA0050 Post-treatment controllers exhibit distinct CD8+ T cell features before and after ART interruptionE-posterHost immune responses, vaccines and immunotherapies
41 - 50 of 1427 items